Next Article in Journal
The Potential Price and Access Implications of the Cost-Utility and Budget Impact Methodologies Applied by NICE in England and ICER in the US for a Novel Gene Therapy in Parkinson’s Disease
Previous Article in Journal
Approaches to Manage ‘Affordability’ of High Budget Impact Medicines in Key EU Countries
 
 
Journal of Market Access & Health Policy (JMAHP) is published by MDPI from Volume 12 Issue 1 (2024). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Taylor & Francis.
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Cost-Effectiveness of Edoxaban Compared to Warfarin for the Treatment and Secondary Prevention of Venous Thromboembolism in the UK

1
Health Economic Outcome Research, Creativ-Ceutical, Paris, France
2
Department of Cardiovascular Sciences, University of Leuven, Leuven, Belgium
3
Department of Thrombosis and Haemostasis, Guy’s & St. Thomas’ Hospital, London, UK
4
School for Health and Related Research, University of Sheffield, Sheffield, UK
5
Market Access, Daiichi Sankyo Europe, Munich, Germany
*
Author to whom correspondence should be addressed.
J. Mark. Access Health Policy 2018, 6(1), 1495974; https://doi.org/10.1080/20016689.2018.1495974
Submission received: 27 March 2018 / Revised: 1 January 2018 / Accepted: 27 June 2018 / Published: 17 July 2018

Abstract

Background: Venous thromboembolism (VTE), which includes pulmonary embolism (PE) and deep vein thrombosis (DVT), is the third most common acute cardiovascular disease and represents an important burden for patients and payers. Objective: The aim was to estimate the cost-effectiveness of edoxaban, a non-VKA oral anticoagulant vs. warfarin, the currently most prescribed treatment for VTE in the UK. Study design: A Markov model was built using data from the Hokusai-VTE randomised controlled trial to estimate the lifetime costs and quality-adjusted life years (QALYs) in patients with VTE treated with edoxaban or warfarin over a lifetime horizon, from the UK National Health Services perspective. The model included VTE recurrences, VTE-related complications (post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension), and several types of bleeds associated with anticoagulation treatment. Patients were treated during a period of 6 months after the first VTE event, followed by flexible treatment duration (from 6 months to lifetime) after recurrence, i.e., tertiary prevention. Results: Edoxaban was found dominant vs. warfarin with 0.033 additional QALY and £55 less costs. The reduction of patient management costs, specifically monitoring costs, outweighed the higher drug costs. Edoxaban was dominant in all subgroups (index DVT only, all PE cases (PE with or without DVT), PE without DVT and PE with DVT). Cost-savings ranged from £54 to £81 while additional QALYs ranged from 0.031 to 0.046. Edoxaban was found dominant in 88.6% of cases and cost-effective in additional 10.9% of cases considering a £20,000 threshold in the probabilistic sensitivity analysis. Conclusion: Edoxaban may improve patients’ quality of life in a lifetime horizon without additional costs for the healthcare system due to lower bleeding risk and no monitoring cost compared to warfarin.
Keywords: edoxaban; warfarin; anticoagulant; venous thromboembolism; deep vein thrombosis; pulmonary embolism; economic evaluation; Markov model; cost-effectiveness edoxaban; warfarin; anticoagulant; venous thromboembolism; deep vein thrombosis; pulmonary embolism; economic evaluation; Markov model; cost-effectiveness

Share and Cite

MDPI and ACS Style

Clay, E.; Jamotte, A.; Verhamme, P.; Cohen, A.T.; Van Hout, B.A.; Gumbs, P. Cost-Effectiveness of Edoxaban Compared to Warfarin for the Treatment and Secondary Prevention of Venous Thromboembolism in the UK. J. Mark. Access Health Policy 2018, 6, 1495974. https://doi.org/10.1080/20016689.2018.1495974

AMA Style

Clay E, Jamotte A, Verhamme P, Cohen AT, Van Hout BA, Gumbs P. Cost-Effectiveness of Edoxaban Compared to Warfarin for the Treatment and Secondary Prevention of Venous Thromboembolism in the UK. Journal of Market Access & Health Policy. 2018; 6(1):1495974. https://doi.org/10.1080/20016689.2018.1495974

Chicago/Turabian Style

Clay, Emilie, Aurélien Jamotte, Peter Verhamme, Alexander T. Cohen, Ben. A. Van Hout, and Pearl. Gumbs. 2018. "Cost-Effectiveness of Edoxaban Compared to Warfarin for the Treatment and Secondary Prevention of Venous Thromboembolism in the UK" Journal of Market Access & Health Policy 6, no. 1: 1495974. https://doi.org/10.1080/20016689.2018.1495974

Article Metrics

Back to TopTop